Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term chemotherapy. Found 241 abstracts

no pagination
Landau H, Pandit-Taskar N, Hassoun H, Cohen A, Lesokhin A, Lendvai N, Drullinsky P, Schulman P, Jhanwar S, Hoover E, Bello C, Riedel E, Nimer SD, Comenzo RL. Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease. Leukemia & lymphoma. 2012 Feb;53(2):275-81.
Makhov PB, Golovine K, Kutikov A, Teper E, Canter DJ, Simhan J, Uzzo RG, Kolenko VM. Modulation of Akt/mTOR Signaling Overcomes Sunitinib Resistance in Renal and Prostate Cancer Cells. Molecular Cancer Therapeutics. 2012 Jul;11(7):1510-7.   PMCID: PMC 3491642
Moore KN, Sill MW, Miller DS, McCourt C, De Geest K, Rose PG, Cardenes HR, Mannel RS, Farley JH, Schilder RJ, Fracasso PM. A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study. Gynecologic Oncology. 2012 Dec;127(3):456-61.   PMCID: *
Morgan RJ, Alvarez RD, Armstrong DK, Burger RA, Castells M, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray H, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Remmenga SW, Sabbatini P, Santoso JT, Schilder RJ, Schink J, Teng N, Werner TL, Hughes M, Dwyer MA. Ovarian Cancer, Version 3.2012 Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network. 2012 Nov;10(11):1339-49.
Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Buyyounouski MK, Carducci MA, Chang SS, Choueiri TK, Gupta S, Hancock SL, Hudes GR, Jonasch E, Kuzel TM, Lau C, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Wang J, Wilder RB. Testicular Cancer Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2012 Apr;10(4):502-35.   PMCID: not NIH funded
Pfister DG, Ang KK, Brizel DM, Burtness B, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL, Hitchcock YJ, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pinto HA, Ridge JA, Samant S, Sanguineti G, Schuller DE. Mucosal Melanoma of the Head and Neck. Journal of the National Comprehensive Cancer Network. 2012 Mar;10(3):320-38.   PMCID: not NIH Funded
Pro B, Perini GF. Brentuximab vedotin in Hodgkin's lymphoma. Expert Opinion on Biological Therapy. 2012 Oct;12(10):1415-21.   PMCID: Not NIH Funded
Sparano JA, Goldstein LJ, Davidson NE, Sledge GW, Gray R. TOP2A RNA expression and recurrence in estrogen receptor-positive breast cancer. Breast Cancer Research and Treatment. 2012 Jul;134(2):751-7.
Stehman FB, Brady MF, Thigpen JT, Rossi EC, Burger RA. Cytokine use and survival in the first-line treatment of ovarian cancer: A Gynecologic Oncology Group Study. Gynecologic Oncology. 2012 Dec;127(3):495-501.   PMCID: PMC3496007
Swisher SG, Winter KA, Komaki RU, Ajani JA, Wu TT, Hofstetter WL, Konski AA, Willett CG. A PHASE II STUDY OF A PACLITAXEL-BASED CHEMORADIATION REGIMEN WITH SELECTIVE SURGICAL SALVAGE FOR RESECTABLE LOCOREGIONALLY ADVANCED ESOPHAGEAL CANCER: INITIAL REPORTING OF RTOG 0246. International Journal of Radiation Oncology Biology Physics. 2012 Apr;82(5):1967-72.   PMCID: *
Wong SJ, Winter K, Meropol NJ, Anne PR, Kachnic L, Rashid A, Watson JC, Mitchell E, Pollock J, Lee RJ, Haddock M, Erickson BA, Willett CG. RADIATION THERAPY ONCOLOGY GROUP 0247: A RANDOMIZED PHASE II STUDY OF NEOADJUVANT CAPECITABINE AND IRINOTECAN OR CAPECITABINE AND OXALIPLATIN WITH CONCURRENT RADIOTHERAPY FOR PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER. International Journal of Radiation Oncology Biology Physics. 2012 Mar;82(4):1367-75.   PMCID: PMC3208721
Wong YN, Litwin S, Vaughn D, Cohen S, Plimack ER, Lee J, Song W, Dabrow M, Brody M, Tuttle H, Hudes G. Phase II Trial of Cetuximab With or Without Paclitaxel in Patients With Advanced Urothelial Tract Carcinoma. Journal of Clinical Oncology. 2012 Oct;30(28):3545-51.   PMCID: PMC3454772
Ajani JA, Barthel JS, Bentrem DJ, D'Amico TA, Das P, Denlinger CS, Fuchs CS, Gerdes H, Glasgow RE, Hayman JA, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Korn M, Lockhart AC, Mulcahy MF, Orringer MB, Osarogiagbon RU, Posey JA, Sasson AR, Scott WJ, Shibata S, Strong VE, Varghese TK, Warren G, Washington MK, Willett C, Wright CD, Meron Aj VP. Esophageal and Esophagogastric Junction Cancers. Journal of the National Comprehensive Cancer Network. 2011 Aug;9(8):830-+.   PMCID: not NIH funded
Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD, Devine S, Djulbegovic B, Faber EA, Gasparetto C, Huff CA, Kassim A, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Tricot G, Weber DM, Yahalom J, Yunus F. Multiple Myeloma. Journal of the National Comprehensive Cancer Network. 2011 Oct;9(10):1146-83.   PMCID: not NIH funded
Bell-McGuinn KM, Matthews CM, Ho SN, Barve M, Gilbert L, Penson RT, Lengyel E, Palaparthy R, Gilder K, Vassos A, McAuliffe W, Weymer S, Barton J, Schilder RJ. A phase II, single-arm study of the anti-alpha 5 beta 1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecologic Oncology. 2011 May;121(2):273-9.   PMCID: not NIH funded
Brem SS, Bierman PJ, Brem H, Butowski N, Chamberlain MC, Chiocca EA, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Hesser D, Junck L, Linette GP, Loeffler JS, Maor MH, Michael M, Moots PL, Morrison T, Mrugala M, Nabors LB, Newton HB, Portnow J, Raizer JJ, Recht L, Shrieve DC, Sills AK, Vrionis FD, Wen PY. Central Nervous System Cancers. Journal of the National Comprehensive Cancer Network. 2011 Apr;9(4):352-400.   PMCID: not NIH funded
Carlson RW, Allred C, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Sachdev J, Smith ML, Somlo G, Ward JH, Wolff AC, Zellars R. Invasive Breast Cancer. Journal of the National Comprehensive Cancer Network. 2011 Feb;9(2):136-222.   PMCID: not NIH funded - practice guideline
Chakravarty A, Shinde V, Tabernero J, Cervantes A, Cohen RB, Dees EC, Burris H, Infante JR, Macarulla T, Elez E, Andreu J, Rodriguez-Braun E, Rosello S, von Mehren M, Meropol NJ, Langer CJ, Oneil B, Bowman D, Zhang M, Danaee H, Faron-Yowe L, Gray G, Liu H, Pappas J, Silverman L, Simpson C, Stringer B, Tirrell S, Veiby OP, Venkatakrishnan K, Galvin K, Manfredi M, Ecsedy JA. Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A Kinase. Cancer Research. 2011 Feb;71(3):675-85.   PMCID: not NIH funded
Chun YS, Cooper HS, Cohen SJ, Konski A, Burtness B, Denlinger CS, Astsaturov I, Hall MJ, Hoffman JP. Significance of Pathologic Response to Preoperative Therapy in Pancreatic Cancer. Annals of Surgical Oncology. 2011 Dec;18(13):3601-7.   PMCID: not NIH funded
Crawford J, Allen J, Armitage J, Blayney DW, Cataland SR, Heaney ML, Htoy S, Hudock S, Kloth DD, Kuter DJ, Lyman GH, McMahon B, Steensma DP, Vadhan-Raj S, Westervelt P, Westmoreland M. Myeloid Growth Factors. Journal of the National Comprehensive Cancer Network. 2011 Aug;9(8):914-+.   PMCID: not NIH funded
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term chemotherapy

chemotherapy NCCN Clinical Practice Guidelines NCCN Guidelines therapy gemcitabine bevacizumab chemoradiotherapy phase-iii trial positron-emission-tomography randomized controlled-trial dexamethasone adjuvant therapy squamous-cell carcinoma radiation cancer phase-ii trial angiogenesis trial head multicenter term-follow-up high-dose surgery combination phase-ii Chemotherapy expression cisplatin doxorubicin breast-cancer resection stem-cell transplantation carcinoma pegylated liposomal doxorubicin chemoradiation randomized-trial radiotherapy biopsy renal germ-cell tumors cell lung-carcinoma indiana-university experience donor lymphocyte infusions drug hypersensitivity medulloblastoma kit mutation tamoxifen gene-expression bone-marrow transplantation 1995 ow wh-v274-p474 i liposomal colony-stimulating factor placebo-controlled trial cytogenetics human lactate dehydrogenase prognosis fallopian-tube open-label rates bladder-cancer gamma-knife surgery apoptosis 1987 arlson me-journal of chronic diseases-v40-p373 sgn-30 alpha(5)beta(1) integrin thalidomide plus intensity-modulated radiotherapy plus cetuximab high-grade dysplasia bisphosphonates high response ii colorectal-cancer cervical-cancer consensus statement proteasome inhibitor primary amyloidosis surgical adjuvant brain tumor 2010 ung pw-j clin oncol-v28 salvage chemotherapy Platinum resistant minimally invasive esophagectomy Cancer carboplatin postoperative radiotherapy anemia oncology-group PTEN (JNCCN 2011 hematologic malignancies 2011 ung p-j natl cancer i-v103-p194 Volociximab plus irinotecan Rectal pathway concurrent failure seminoma metastatic preoperative radiotherapy Ovarian cancer 2009 carthy pl-blood-v114 radiation therapy Salvage surgery stem cell transplant head and neck cancer cancer-patients induced febrile 2002 ung p-can j urol-v9-p1637 hypersensitivity reactions glioblastoma signature multidisciplinary care 1975 cock sj-biometrics-v31-p103 radiation-therapy comorbidity index Multiple myeloma 1995 evallier b-v13-p1564 pathology quality-of-life circulating tumor-cells cell-division radiotherapy plus concomitant sentinel-node biopsy biologic therapy C-reactive protein carcinomas lenalidomide esophageal controlled phase-iii cell lung-cancer lymph-node dissection hypersensitivity alpha 5 beta 1 integrin squamous-cell-carcinoma stage-i seminoma breast cancer metaanalysis brain radiation-therapy primary transitional-cell carcinoma 2nd-line treatment Chemoradiation Waldenstrom's monoclonal protein lobular carcinoma in situ tyrosine kinase inhibitors antimitotic drugs alpha
Last updated on Thursday, June 04, 2020